1. Home
  2. TYRA vs DAKT Comparison

TYRA vs DAKT Comparison

Compare TYRA & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • DAKT
  • Stock Information
  • Founded
  • TYRA 2018
  • DAKT 1968
  • Country
  • TYRA United States
  • DAKT United States
  • Employees
  • TYRA N/A
  • DAKT N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • DAKT Office Equipment/Supplies/Services
  • Sector
  • TYRA Health Care
  • DAKT Industrials
  • Exchange
  • TYRA Nasdaq
  • DAKT Nasdaq
  • Market Cap
  • TYRA 844.2M
  • DAKT 991.0M
  • IPO Year
  • TYRA 2021
  • DAKT 1994
  • Fundamental
  • Price
  • TYRA $22.01
  • DAKT $19.26
  • Analyst Decision
  • TYRA Strong Buy
  • DAKT Strong Buy
  • Analyst Count
  • TYRA 5
  • DAKT 1
  • Target Price
  • TYRA $31.20
  • DAKT $26.00
  • AVG Volume (30 Days)
  • TYRA 448.1K
  • DAKT 367.7K
  • Earning Date
  • TYRA 11-05-2025
  • DAKT 12-10-2025
  • Dividend Yield
  • TYRA N/A
  • DAKT N/A
  • EPS Growth
  • TYRA N/A
  • DAKT 9.66
  • EPS
  • TYRA N/A
  • DAKT 0.23
  • Revenue
  • TYRA N/A
  • DAKT $749,361,000.00
  • Revenue This Year
  • TYRA N/A
  • DAKT $12.94
  • Revenue Next Year
  • TYRA N/A
  • DAKT $7.16
  • P/E Ratio
  • TYRA N/A
  • DAKT $81.69
  • Revenue Growth
  • TYRA N/A
  • DAKT N/A
  • 52 Week Low
  • TYRA $6.42
  • DAKT $10.24
  • 52 Week High
  • TYRA $22.68
  • DAKT $24.38
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 83.81
  • DAKT 53.51
  • Support Level
  • TYRA $14.84
  • DAKT $17.17
  • Resistance Level
  • TYRA $22.68
  • DAKT $18.42
  • Average True Range (ATR)
  • TYRA 1.57
  • DAKT 0.64
  • MACD
  • TYRA 0.71
  • DAKT 0.08
  • Stochastic Oscillator
  • TYRA 94.18
  • DAKT 94.57

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

Share on Social Networks: